Healthcare
Tong Ren Tang Technologies Co. Ltd.(TGRNF)
Live Price
Offline$0.4949
+0.00% today
1Y Change
-19.84%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $4.38B
- Revenue Growth
- -13.0%
- EPS Growth
- -26.8%
- Dividend Yield
- 5.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tong Ren Tang Technologies Co. Ltd. (TGRNF) is a Healthcare stock with a market cap of $4.38B and listed on OTC. The stock last traded around $0.49 and down 19.8% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -13.0%, EPS growth of -26.8%, a dividend yield of 5.0%. What stands out right now is revenue -13.0%, EPS -26.8%, free cash flow +1011.7% with operating margin 12.5% and ROIC 5.2%. The dividend matters to the case here, with a current yield around 5.0%. Valuation is more restrained than many high-expectation growth names at P/E 11.1 and price/sales 0.7. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines TGRNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-13.0% vs +7.6% peer median
Operating Margin
Below sector median
+12.5% vs +19.4% peer median
P/E
Below sector median
11.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 27, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -13.0% and EPS is at -26.8%, with operating margin around 12.5%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 20, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 27, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 20, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Sep 1, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TGRNF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TGRNF Max Drawdown
-29.30%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TGRNF and SPY.
Company Overview
Tong Ren Tang Technologies Co. Ltd.
Other OTC
Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicine products in Mainland China and Hong Kong. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, and foot care products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in the technological development and sale of biological products, Chinese and Western medicines, cosmetics, and healthcare products; wholesale and retail sale of Chinese medicines and healthcare products; and internal and external surgery, medical examination, and hospital management activities. Further, it produces and processes biochemical products; extracts and processes plants; and produces food and daily chemical products, and medical services. The company was founded in 1669 and is based in Beijing, the People's Republic of China.
- Leadership
- Yi Zhang
- IPO Date
- Aug 17, 2012
- Employees
- 4.0k
- Street Address
- No. 20 Nansanhuan Zhonglu Road
- Mailing
- Beijing, 100079
- Region
- Beijing, CN
- Reporting Currency
- USD
- Investor Line
- 86 10 8763 2888
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 11.1
- EV/EBITDA
- 1.7
- Price/Sales
- 0.7
- Price/Book
- 0.6
Growth
- Revenue
- -13.0%
- EPS
- -26.8%
- Free Cash Flow
- +1011.7%
Profitability
- Gross Margin
- 38.0%
- Operating Margin
- 12.5%
- Net Margin
- 6.1%
- ROE
- 5.4%
- ROIC
- 5.2%
Balance Sheet
- Debt/Equity
- 0.30
- Current Ratio
- 5.72
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.